Low Molecular Weight Cationic Lipids for siRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional cationic lipids used for siRNA delivery, such as CLinDMA and DLinDMA, suffer from non-optimal delivery efficiency and liver toxicity at higher doses, limiting their efficacy and safety.
Innovation Solution
Development of novel low molecular weight cationic lipids with a short lipid chain and hydrolysable functionality, combined with cholesterol and PEG-lipids, to form lipid nanoparticles that enhance siRNA delivery efficiency and reduce liver toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cationic lipids (CLinDMA, DLinDMA) are used for siRNA delivery, then delivery efficiency is achieved, but liver toxicity occurs at higher doses
Solution Approach 1:
The patent changes the molecular weight parameter of the cationic lipid by using shorter lipid chains (C12-C18 instead of longer chains), which reduces the lipid's accumulation in the liver and thereby decreases toxicity while maintaining delivery efficiency
Solution Approach 2:
The patent creates a composite lipid nanoparticle system combining novel low molecular weight cationic lipids with cholesterol and PEG-lipids, where each component contributes specific properties that collectively improve delivery efficiency while reducing liver toxicity through controlled composition ratios
2Object-affected harmful factors
If low molecular weight cationic lipids with short lipid chains are used, then liver toxicity is reduced, but delivery efficiency may be compromised
Solution Approach 1:
The patent compensates for the potentially reduced delivery efficiency of low molecular weight lipids by formulating composite nanoparticles with cholesterol (which enhances membrane interaction) and PEG-lipids (which provide stabilization and extended circulation), achieving both reduced toxicity and maintained efficiency
Solution Approach 2:
The patent optimizes the local properties of different lipid components within the nanoparticle, where the cationic lipid provides transfection capability, cholesterol provides membrane fusion properties, and PEG-lipid provides steric stabilization, with each component's concentration optimized for its specific function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipids demonstrate improved delivery efficacy and reduced liver toxicity, allowing for more effective and tolerable in vivo siRNA delivery while minimizing adverse effects.
Implementation Method 1
inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA
Data Source
AI summary
The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.